drugset / Trial / NCT01864226

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers

NCT01864226

Phase 1 Completed 44 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blind

Summary

This single-center, randomized, investigator/subject-blind, adaptive multiple ascending-dose, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5545965 in healthy volunteers. Subjects will be randomized to receive either RO5545965 or matching placebo daily for 12 days.

Timeline

Start
2013-06
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject RO5545965 Unknown Oral

Indications

No indication recorded.